- Article
- Source: Campus Sanofi
- 23 Oct 2023
Benefits of switching to Toujeo (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes
Real-World Evidence Studies
Patient satisfaction with Toujeo® (insulin glargine 300 Units/mL) in adults with T2D
Treatment persistence with basal insulin in adults with T2D
Hospitalisation rates with basal insulin in adults with T2D
Patient satisfaction with Toujeo® (insulin glargine 300 Units/mL) in adults with T2D
Treatment persistence with basal insulin in adults with T2D
Hospitalisation rates with basal insulin in adults with T2D
T1 Case Studies
.jpg)
A Young Patient with Deteriorating Glycaemic Control
%20(1).png)
Wide Glycaemic Variability
.png)
Wide Glycaemic Variability with Frequent Hypoglycaemia in a Young Patient
%20(2).png)
Poor Glucose Control in a Young Patient with Comorbid Depression
.png)
Wide glycaemic variability
%20(3).png)
Hypoglycaemia with severe nocturnal hypoglycaemic episodes
%20(4).png)
A young patient with poor glucose management and disordered eating behaviour
%20(5).png)
Nocturnal hypoglycaemia and the somogyi phenomenon
A Young Patient with Deteriorating Glycaemic Control
Wide Glycaemic Variability
Wide Glycaemic Variability with Frequent Hypoglycaemia in a Young Patient
Poor Glucose Control in a Young Patient with Comorbid Depression
Wide glycaemic variability
Hypoglycaemia with severe nocturnal hypoglycaemic episodes
A young patient with poor glucose management and disordered eating behaviour
Nocturnal hypoglycaemia and the somogyi phenomenon
T2 Case Studies
Apparent Glycemic Control
Patient with Poorly Controlled T2DM
Elderly Patient with T2DM
Glycemic Variability and Nocturnal Hypoglycemia
Apparent Glycemic Control
Patient with Poorly Controlled T2DM
Elderly Patient with T2DM
Glycemic Variability and Nocturnal Hypoglycemia
Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.7
For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >
Diabetes Products
References
1. Colin IM, et al. Diabetes Ther. 2020;11:1835–1847
7. Toujeo Summary of Product Characteristics
MAT-XU-2302861 (v6.0) Date of Preparation: October 2024